newsfilter
← Latest News
PR Newswire·

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

  • AbbVie has entered a new collaboration with Valkai to deepen its investment in artificial intelligence infrastructure.
  • The partnership aims to integrate purpose-built AI capabilities across clinical development to accelerate scientific innovation.
  • Deployed AI tools are designed to improve efficiency in clinical research, generate insights faster, & reduce development timelines.
  • Nicholas Donoghoe, AbbVie's executive vice president, stated the alliance helps teams handle complex data while focusing on critical decisions.
  • Valkai CEO Vignesh Rajendran highlighted the combination of advanced AI with AbbVie's scale & patient-focused innovation.
  • Andrew Campbell, AbbVie's vice president of clinical sciences, noted AI can reduce manual processes to allow more focus on clinical strategy.
  • The initiative supports AbbVie's enterprise AI@AbbVie approach to enhance productivity & decision-making across R&D & operations.
  • Valkai operates as an AI platform for life sciences, founded by experts from companies including OpenAI & Google DeepMind.